Brokerages Set Diploma PLC (LON:DPLM) Price Target at GBX 5,605.71

Shares of Diploma PLC (LON:DPLM) have been given an average rating of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is GBX 5,634.29.

Several brokerages have recently commented on DPLM. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Diploma from GBX 6,000 to GBX 6,200 and gave the stock a “buy” rating in a report on Wednesday. Berenberg Bank restated a “buy” rating and set a GBX 6,350 price target on shares of Diploma in a research note on Wednesday, November 19th. Peel Hunt reaffirmed a “buy” rating and issued a GBX 6,150 price objective on shares of Diploma in a research note on Friday, December 19th. Finally, Royal Bank Of Canada upgraded Diploma to an “outperform” rating and boosted their price objective for the company from GBX 4,500 to GBX 6,000 in a report on Friday, October 3rd.

Key Stories Impacting Diploma

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Q1 trading: Diploma reported a 14% jump in organic revenue for Q1 and raised its M&A guidance, which underpins the firm’s growth story and supports higher forward earnings expectations. Investing.com article
• Positive Sentiment: Analyst upgrade: Deutsche Bank raised its price target from GBX 6,000 to GBX 6,200 and set a “buy” rating, signaling stronger sell-side conviction and providing a clear upside reference for investors. Digital Look broker note
• Positive Sentiment: Board-level buying: Non-executive directors Ian El‑Mokadem and Katie Bickerstaffe have increased their personal holdings, a vote of confidence from the board that reduces governance-related uncertainty. TipRanks announcement
• Positive Sentiment: Insider purchases: Two insiders made open-market buys (Ian El‑Mokadem ~500 shares at ~GBX 5,615; Katie Bickerstaffe ~352 shares at ~GBX 5,645), reinforcing management/board confidence in the share price. MarketBeat filings

Diploma Stock Performance

LON DPLM opened at GBX 5,690 on Friday. The stock has a fifty day simple moving average of GBX 5,411.02 and a 200-day simple moving average of GBX 5,351.16. The company has a current ratio of 2.17, a quick ratio of 0.80 and a debt-to-equity ratio of 62.17. The stock has a market cap of £7.63 billion, a PE ratio of 41.44, a P/E/G ratio of 2.82 and a beta of 0.75. Diploma has a twelve month low of GBX 3,532 and a twelve month high of GBX 5,760.

Diploma (LON:DPLM) last posted its earnings results on Monday, December 8th. The company reported GBX 176 EPS for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. Equities analysts anticipate that Diploma will post 163.7995512 earnings per share for the current year.

Insider Buying and Selling at Diploma

In other Diploma news, insider Katie Bickerstaffe purchased 352 shares of the firm’s stock in a transaction on Wednesday, January 14th. The stock was bought at an average price of GBX 5,645 per share, with a total value of £19,870.40. Also, insider Ian El-Mokadem purchased 500 shares of the company’s stock in a transaction on Wednesday, January 14th. The stock was acquired at an average price of GBX 5,615 per share, with a total value of £28,075. Over the last ninety days, insiders have bought 2,012 shares of company stock worth $9,993,580. 1.13% of the stock is currently owned by company insiders.

Diploma Company Profile

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.